Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Asarone is a phenylpropanoid compound naturally occurring in plants of the *Acorus* genus, such as *Acorus tatarinowii*. It exists primarily as two isomers, alpha-asarone and beta-asarone, with alpha-asarone being widely studied for its pharmacological effects on the central nervous system. The drug is being developed as a neuroprotective agent for the treatment of ischemic stroke, where it is thought to exert its effects by modulating GABAergic neurotransmission, inhibiting neuroinflammation, and reducing oxidative stress. Chengdu Xinrui Taikang Technology is currently evaluating TK-03, an injectable emulsion formulation of asarone, in Phase 1 clinical trials to assess its safety, tolerability, and pharmacokinetics in healthy volunteers and potentially stroke patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on asarone.